Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 11;11(1):3690.
doi: 10.1038/s41598-021-83099-y.

Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system

Bin Wu  1 , Dan Li  1   2 , Ting Xu  3   4 , Min Luo  1 , Zhiyao He  1 , Yuwen Li  1
Affiliations

Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system

Bin Wu et al. Sci Rep. .

Abstract

Proton pump inhibitors (PPIs) were widely used. Observational studies suggested increasing risk of kidney injury in patients with PPIs treatment. We gathered six PPI regimens and adverse reports of acute kidney injury (AKI) and chronic kidney disease (CKD) based on US FDA Adverse Event Reporting System (FAERS) database from 2004 to 2019. We employed reporting odds ratio (ROR) to detect signals. Finally, we identified 3187 PPIs-associated AKI cases and 3457 PPIs-associated CKD cases. We detected significant signals between PPIs and AKI as well as CKD. The signal strength was stronger for CKD (ROR = 8.80, 95% CI 8.49-9.13) than AKI (ROR = 3.95, 95% CI 3.81-4.10), while dexlansoprazole performed stronger association for CKD (ROR = 34.94, 95% CI 30.89-39.53) and AKI (ROR = 8.18, 95% CI 7.04-9.51) than the other five PPIs. The median time from PPIs use to event occurrence was 23 days for AKI and 177 days for CKD. PPIs-associated AKI resulted larger proportion of death, life-threatening, hospitalization and disability events than PPIs-associated CKD. By mining the FAERS big data, we provided more information between PPIs use and the AKI and CKD events. PPIs rational use should be repeatedly stressed.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Flow chart of identifying PPI associated AKI and CKD cases from FAERS database.
Figure 2
Figure 2
Indications of PPIs associated AKI and CKD cases from FAERS database. PPIs proton pump inhibitors, AKI acute kidney injury, CKD chronic kidney disease.
Figure 3
Figure 3
Time interval from PPIs use to AKI and CKD events occurrence from FAERS database. PPIs proton pump inhibitors, AKI acute kidney injury, CKD chronic kidney disease.
Figure 4
Figure 4
Median time from PPIs use to events occurrence from FAERS database. PPIs proton pump inhibitors, AKI acute kidney injury, CKD chronic kidney disease.
See this image and copyright information in PMC

References

    1. Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: A comprehensive review. Gut Liver. 2017;11:27–37. doi: 10.5009/gnl15502. - DOI - PMC - PubMed
    1. Ying J, Li LC, Wu CY, Yu ZW, Kan LD. The status of proton pump inhibitor use: A prescription survey of 45 hospitals in China. Rev. Esp. Enferm. Dig. 2019;111:738–743. doi: 10.17235/reed.2019.6155/2019. - DOI - PubMed
    1. Pasina L, Novella A, Elli C, Nobili A, Ianes A. Overuse of proton pump inhibitors in nursing homes: An Italian multicenter observational study. Pharmacoepidemiol. Drug Saf. 2020;29:461–466. doi: 10.1002/pds.4963. - DOI - PubMed
    1. Haastrup PF, Thompson W, Søndergaard J, Jarbøl DE. Side effects of long-term proton pump inhibitor use: A review. Basic Clin. Pharmacol. Toxicol. 2018;123:114–121. doi: 10.1111/bcpt.13023. - DOI - PubMed
    1. Perry IE, Sonu I, Scarpignato C, Akiyama J, Hongo M, Vega KJ. Potential proton pump inhibitor-related adverse effects. Ann. N. Y. Acad. Sci. 2020 doi: 10.1111/nyas.14428. - DOI - PubMed

MeSH terms

Substances